Log in

NASDAQ:AGRXAgile Therapeutics Stock Price, Forecast & News

$2.87
+0.02 (+0.70 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.82
Now: $2.87
$2.97
50-Day Range
$2.10
MA: $2.62
$3.19
52-Week Range
$0.35
Now: $2.87
$4.77
Volume1.62 million shs
Average Volume1.76 million shs
Market Capitalization$250.29 million
P/E RatioN/A
Dividend YieldN/A
Beta1.49
Agile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Read More
Agile Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.23 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AGRX
CUSIPN/A
Phone609-683-1880

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.77 per share

Profitability

Net Income$-18,610,000.00

Miscellaneous

Employees13
Market Cap$250.29 million
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive AGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AGRX and its competitors with MarketBeat's FREE daily newsletter.

Agile Therapeutics (NASDAQ:AGRX) Frequently Asked Questions

How has Agile Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Agile Therapeutics' stock was trading at $1.94 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AGRX stock has increased by 47.9% and is now trading at $2.87. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Agile Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Agile Therapeutics.

When is Agile Therapeutics' next earnings date?

Agile Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Agile Therapeutics.

How were Agile Therapeutics' earnings last quarter?

Agile Therapeutics Inc (NASDAQ:AGRX) issued its quarterly earnings data on Tuesday, May, 5th. The specialty pharmaceutical company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. View Agile Therapeutics' earnings history.

What guidance has Agile Therapeutics issued on next quarter's earnings?

Agile Therapeutics issued an update on its fourth quarter 2020 After-Hours earnings guidance on Tuesday, May, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4-6 million.

What price target have analysts set for AGRX?

6 brokers have issued 12-month target prices for Agile Therapeutics' shares. Their forecasts range from $3.00 to $9.00. On average, they expect Agile Therapeutics' stock price to reach $6.20 in the next year. This suggests a possible upside of 116.0% from the stock's current price. View analysts' price targets for Agile Therapeutics.

Has Agile Therapeutics been receiving favorable news coverage?

Headlines about AGRX stock have trended somewhat negative recently, according to InfoTrie. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Agile Therapeutics earned a news sentiment score of -1.6 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutAgile Therapeutics.

Who are some of Agile Therapeutics' key competitors?

What other stocks do shareholders of Agile Therapeutics own?

Who are Agile Therapeutics' key executives?

Agile Therapeutics' management team includes the following people:
  • Mr. Alfred F. Altomari, Chairman & CEO (Age 60)
  • Mr. Scott M. Coiante, CFO & Sr. VP (Age 52)
  • Dr. Elizabeth Ijeoma Onyemelukwe Garner, Sr. VP & Chief Medical Officer (Age 51)
  • Mr. Geoffrey P. Gilmore, Gen. Counsel (Age 53)
  • Mr. Robert G. Conway, Sr. VP of Enterprise Planning & Information Management (Age 62)

What is Agile Therapeutics' stock symbol?

Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."

Who are Agile Therapeutics' major shareholders?

Agile Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (18.25%), BlackRock Inc. (1.44%), Orbimed Advisors LLC (1.38%), Geode Capital Management LLC (0.68%), First Midwest Bank Trust Division (0.54%) and DG Capital Management LLC (0.26%). Company insiders that own Agile Therapeutics stock include Abhijeet J Lele, Alfred Altomari, Dennis Reilly, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View institutional ownership trends for Agile Therapeutics.

Which major investors are buying Agile Therapeutics stock?

AGRX stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Orbimed Advisors LLC, First Midwest Bank Trust Division, BlackRock Inc., DG Capital Management LLC, Geode Capital Management LLC, Advisor Group Holdings Inc., and Thrivent Financial for Lutherans. Company insiders that have bought Agile Therapeutics stock in the last two years include Abhijeet J Lele, Alfred Altomari, Dennis Reilly, Life Sciences Maste Perceptive, and Perceptive Advisors Llc. View insider buying and selling activity for Agile Therapeutics.

How do I buy shares of Agile Therapeutics?

Shares of AGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Agile Therapeutics' stock price today?

One share of AGRX stock can currently be purchased for approximately $2.87.

How big of a company is Agile Therapeutics?

Agile Therapeutics has a market capitalization of $250.29 million. The specialty pharmaceutical company earns $-18,610,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. Agile Therapeutics employs 13 workers across the globe.

What is Agile Therapeutics' official website?

The official website for Agile Therapeutics is www.agiletherapeutics.com.

How can I contact Agile Therapeutics?

Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The specialty pharmaceutical company can be reached via phone at 609-683-1880 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.